Monopar Therapeutics
MNPR
35 hedge funds and large institutions have $109M invested in Monopar Therapeutics in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.
1,700% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 1
94% more funds holding
Funds holding: 18 → 35 (+17)
91% more capital invested
Capital invested by funds: $57.1M → $109M (+$52.2M)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
4.91% more ownership
Funds ownership: 42.41% → 47.31% (+4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$3.15M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$2.23M |
| 3 |
Millennium Management
New York
|
+$2.18M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$936K |
| 5 |
Goldman Sachs
New York
|
+$666K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$1.05M |
| 2 |
Morgan Stanley
New York
|
-$85.7K |
| 3 |
JP Morgan Chase
New York
|
-$69.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$45.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NA
26
NewEdge Advisors
New Orleans,
Louisiana
| $21.8K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $11K | -$14.2K | -393 | -56% |
|
28
Wells Fargo
San Francisco,
California
| $9.1K | – | – | – |
|
29
Citigroup
New York
| $8.19K | +$8.11K | +225 | New |
|
|
PD
30
Point72 (DIFC)
Dubai,
United Arab Emirates
| $7.13K | +$7.06K | +196 | New |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | +$7.39K | +205 | New |
|
|
AF
32
Allworth Financial
Folsom,
California
| $4.46K | +$3.6K | +100 | New |
|
|
33
JP Morgan Chase
New York
| $3.64K | -$69.8K | -1,937 | -95% |
|
|
FDCDDQ
34
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $583 | – | – | – |
|
35
Barclays
London,
United Kingdom
| $437 | +$432 | +12 | New |
|
|
SS
36
SBI Securities
Tokyo,
Japan
| – | -$2.2K | -100 | Closed |
|
MNPR Hedge Fund Activity: Q1 2025 in Review
35 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2025, worth a combined $109M — up 91% from $57.1M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MNPR positions and 1 closed out — a net gain of 17 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $3.15M. The largest seller was ADAR1 Capital Management, cutting an estimated $1.05M.
- 35 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2025, up from 18 in Q4 2024.
- Funds reported $109M of Monopar Therapeutics stock for Q1 2025, up 91% quarter-over-quarter.
- 18 funds opened new Monopar Therapeutics positions in Q1 2025 and 1 closed out, a net change of +17 holders.
- The largest Monopar Therapeutics buyer in Q1 2025 was Janus Henderson Group, an estimated $3.15M added.
- The largest Monopar Therapeutics seller in Q1 2025 was ADAR1 Capital Management, an estimated $1.05M sold.
Based on aggregated 13F filings for Q1 2025.